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Abstract
Highly aneuploid tumours are common in epithelial ovarian cancers (EOC). We investigated whether NuMA expression was
associated with this phenomenon. NuMA protein levels in normal and tumour tissues, ovarian cell lines and primary
cultures of malignant cells derived from ovarian ascitic fluids were analysed by Affymetrix microarray analysis,
immunoblotting, immunohistochemistry (IHC) and immunofluorescence (IF), with results correlated to associated clinical
data. Aneuploidy status in primary cultures was determined by FACS analysis. Affymetrix microarray data indicated that
NuMA was overexpressed in tumour tissue, primary cultures and cell lines compared to normal ovarian tissue. IHC revealed
low to weak NuMA expression in normal tissues. Expression was upregulated in tumours, with a significant association with
disease stage in mucinous EOC subtypes (p = 0.009), lymph node involvement (p = 0.03) and patient age (p = 0.04).
Additional discontinuous data analysis revealed that high NuMA levels in tumours decreased with grade (p = 0.02) but
increased with disease stage (p = 0.04) in serous EOC. NuMA expression decreased in late disease stage 4 endometrioid
EOCs. High NuMA levels decreased with increased tumour invasion in all subtypes (p = 0.03). IF of primary cultures revealed
that high NuMA levels at mitotic spindle poles were significantly associated with a decreased proportion of cells in
cytokinesis (p = 0.05), increased binucleation (p = 0.021) and multinucleation (p = 0.007), and aneuploidy (p = 0.008). NuMA
is highly expressed in EOC tumours and high NuMA levels correlate with increases in mitotic defects and aneuploidy in
primary cultures.
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Introduction
The 238 kDa nuclear mitotic apparatus (NuMA) protein is a
component of the interphase nucleus and the mitotic spindle pole
matrix [1]. NuMA has functions in spindle assembly through its
association with microtubule motors [2,3] and in spindle
positioning during asymmetric cell division [4]. An additional
interphase role as a nuclear scaffolding protein has been proposed
[4–6]. NuMA is ubiquitously expressed [6,7]. The nuclear and
spindle pole localisations of NuMA are well characterised in
normal tissue [8,9] and in tumour tissues by immunohistochem-
istry (IHC) in the Human Protein Atlas. The role that mitotic
proteins such as NuMA might play in cancer has recently become
a subject of renewed interest as it has become apparent that
aneuploidy is a common feature of tumours that might drive their
progression [10,11].
EOC is a complex disease that is difficult to treat due to late
presentation, disease recurrence after treatment and high rates of
chemo-resistance. The biology of EOC is poorly understood and
improvements to diagnosis and therapy are highly desirable [12].
Ovarian carcinomas are often characterised by karyotypes with
severe aneuploidy due to chromosomal instability (CIN) and
triploidization [13]. It has been proposed that aneuploidy is a
feature of early aberrations in EOC [14]. Aneuploid tumours
respond less favourably to treatment than diploid tumours, leading
to lower survival rates [15]. The NUMA1 gene maps to
chromosome 11q13 [16], a region commonly amplified in ovarian
cancer [17]. However, to our knowledge no publications have
linked NuMA expression to aneuploidy in EOC. We analysed
NuMA levels in primary cultures of malignant cells derived from
ovarian ascitic fluids, in their associated tumour tissues, in tissues
from unrelated primary ovarian tumours and in normal ovarian
tissue using Affymetrix array analysis, slot blotting, IHC and
immunofluorescence (IF). NuMA expression was found to be
upregulated in tumour samples compared to normal controls. IF
analysis of primary cultures identified an association between
increased amounts of NuMA at spindle poles and rates of
binucleation and multinucleation, while FACS analysis revealed a
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positive correlation between increased NuMA expression and
aneuploidy. This study demonstrates for the first time that NuMA
expression is upregulated in EOC and that this is associated with
the aneuploidy seen in this cancer.
Results
Affymetrix Microarray Analysis
Examination of Affymetrix microarray data from a panel of
ovarian cancer cell lines, primary cultures and tumour tissues
showed that NuMA was consistently over-expressed at a
transcriptional level in comparison with normal ovarian tissue.
Only two ascitic samples had lower expression levels compared to
an internal normal control (N) (Figure 1A). This initial work
suggested that further study of NuMA expression in EOCs was
warranted.
Slot Blotting
A total of 35 samples were analysed by slot blotting. This cohort
consisted of 7 established cell lines (JAMA-2, TR175, 1847,
SW480, MCF-7, HeLa and SH-SY5Y), one benign sample (1153-
A1) and 25 primary cultures. Lysates obtained from 2 ovarian
tumour tissues grown in tissue culture (BE4163-T1 and AQ70880-
T1) were also included. A representative example of a slot blot
image of some of the samples is shown in Figure 1B. Normalisation
against an internal a-tubulin control confirmed that there was
variation in NuMA protein levels between the samples tested
(Figure 1C). Among the cell lines, 1847 had the highest NuMA
expression level, followed by TR175 and JAMA-2. The benign
sample 1153-A1 had a medium NuMA level while there was
variation amongst the primary ascites cultures with 3 (1141-A1,
1134-A1 and AE6792-A1) expressing the highest NuMA levels of
all samples. No significant association between the NuMA
immunoblotting results and the associated clinical data was seen.
Reassuringly, NuMA protein levels in general corresponded well
with the RNA expression levels seen for the primary cultures and
ovarian cell lines examined by Affymetrix microarray analysis.
Immunohistochemistry
Immunostaining indicated that NuMA expression in whole
sections of normal ovarian tissue was variable, ranging from very
low to weak levels in stromal and epithelial cell nuclei (n = 7)
(Figure 1D). For the 5 cases of normal tissue with associated
tumour tissue, a clear increase in NuMA expression in 40% (2/5)
of tumour samples was identified. Up to 95% of nuclei in primary
tumours displayed medium to strong NuMA staining (Figure S1a–
d). NuMA was also observed at the spindle poles of mitotic tumour
cells (Figure S1b, arrow). Analysis of a small in-house generated
ovarian cancer TMA revealed that 95% of tumour cell nuclei were
positively stained for NuMA in 24 of 25 cores. Strikingly, analysis
of the data after application of a scoring system that subdivided
samples into low NuMA (all negative, very weak and weak scores)
and high NuMA levels (medium and high scores) showed that high
NuMA levels were only detected in grade 3 tumours (33%;
Figure 1E). Staining of a larger ovarian TMA confirmed low and
high NuMA expression among the cores (Figure 2). Initial analysis
of the overall data regardless of cancer subtype showed that high
NuMA levels increased with tumour grade (from 20.3% for grade
1 tumours to 24.1% for grade 3 tumours, p=0.0016) and disease
stage (an increase from 19.6% for stage 1 to 33.3% for stage 4,
p=0.0077) (data not shown). Analysis of the continuous data for
tumour grade and disease stage, which included subdivision into
the cancer types for which enough data was available (serous,
mucinous and endometrioid), indicated that NuMA expression
correlated with increasing grade in the mucinous subtype
(p=0.009) (Figure 3A). A significant correlation with lymph node
involvement (p=0.03) (Figure 3B) and age (p=0.04) (Figure 3C)
was seen in all subtypes. Further analysis of the results as
discontinuous data (low NuMA vs high NuMA) revealed
additional statistically significant associations. The proportion of
samples with high NuMA levels decreased with grade (p=0.02)
(Figure 3D) and increased in late disease stage in serous EOC
(p=0.04) (Figure 3E). In mucinous EOCs, NuMA levels increased
with grade (p=0.005) (Figure 3F). In late stage endometrioid
EOCs, NuMA expression decreased (Figure 3G) and high NuMA
decreased with an increase in tumour invasion status (p=0.03) (all
subtypes) (Figure 3H). Low NuMA expression was observed in the
entire sample population of 13 clear cell EOCs regardless of
disease stage.
Immunofluorescence Analyses
IF analysis revealed the existence of an interphase nuclear
NuMA staining pattern in all cell lines, one primary culture
adapted as a cell line (GYNA0089) and 23 primary cultures
(Figure 4A, B). In mitosis NuMA was found at the spindle poles
(Figure 4C) in all of the cell lines and primary cultures examined.
Sufficient numbers of mitotic cells for further analysis were
identified in 16 primary cultures. In these samples dividing cells
were examined for mitotic staging and the presence of specific
mitotic defects. Finally, a survey of interphase indicators of
aneuploidy was performed in all samples.
Staining intensities differed amongst the samples (Figure 4). It
was noted that some samples were composed of cells with low level
NuMA staining in interphase nuclei and at mitotic spindle poles
(Figure 4A, a–d and i–l; 4B, C) and some samples were composed
of cells with high NuMA staining intensities (Figure 4A, e–h and
m–p; Figure 4B and C). We also noted that each sample differed
with regards to the proportion of cells at each mitotic stage and
that they exhibited a wide range of mitotic defects. These included
metaphase defects such as tripolar and multipolar spindles
(Figure 5A, a–d) and spindle misalignment (Figure 5A, e);
anaphase defects such as lagging chromosomes and chromosomal
bridging (Figure 5B, a–c); and cytokinetic defects including
chromatid bridging and the generation of unevenly sized daughter
cells (Figure 5C, a–d). Binucleation, multinucleation and the
presence of micronuclei were common defects in interphase cells
(Figure 5D, a–c). The examples shown in Figure 5E were the most
common mitotic errors observed.
A comparison of NuMA staining profiles to mitotic data was
performed. High levels of NuMA in interphase nuclei were
significantly associated with a small proportion of cells in telophase
(p=0.012) and a high proportion of cells displaying a loose
metaphase plate (p = 0.032) (Figure 6A and B). High levels of
NuMA at mitotic spindle poles significantly correlated with high
rates of binucleation (p = 0.021) and multinucleation (p = 0.007)
(Figure 6C and D) and again with loose metaphase plates
(p = 0.041) (Figure 6E). Low levels of NuMA at spindle poles
significantly correlated with a high proportion of cells in
cytokinesis (p = 0.05) (Figure 6F). Interestingly, intermediate levels
of NuMA at the spindle poles significantly correlated with low
error rates in cytokinesis. (p = 0.01) (Figure 6G). To further verify
the data observed in our immunofluorescence analysis of the
primary cultures we immunostained whole sections of solid
tumour tissue from the 23 patients whose ascitic fluids were used
to generate the cultures. This confirmed that solid tumours
displaying high levels of NuMA staining generated primary ascitic
cultures where cells displayed high NuMA expression levels
(Figure S1 a–d). To ascertain that the observed interphase and
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Figure 1. NuMA expression in ovarian cancer cell lines, primary cultures and tissue. A. Affymetrix data showing NuMA over-expression in 6
ovarian cell lines (JAMA-2, IOVE (additional immortalized ovarian epithelial cell line), SKOV-3, TR175, OVCA-433 (in addition) and 1847 (all grey bars,
designated CL), 38 samples of primary cells cultured from ascitic fluid (black bars, designated – A, including some samples with consecutive
collections or passages) and 4 primary cultures established from tumour tissue (designated –T1 to – T4). A1, A2 and A4 are tumour tissue (T1, T2, T4)
associated ascites samples. Intensity values obtained for the samples were normalised to an internal control (normal epithelial ovarian tissue (N)) and
gene expression levels are shown as the ratio of intensity levels/control intensity level as a log10 value. B. NuMA levels in cell lysates. A representative
example of a lysates analysed for NuMA expression by slot blot Black asterix indicates ovarian cell lines (1847, TR175, JAMA-2), brown asterix the
neuroblastoma cell line SH-SY5Y, pink asterix the colon adenocarcinoma cell line SW480, blue asterix the cervical cancer cell line HeLa, and yellow
asterix the breast cancer cell line MCF7. All other samples are lysates from ovarian primary cultures. C. Histogram comparing NuMA levels in ovarian
cell lines, a primary cell line derived from a benign gynaecological disorder (1153-A1) and primary cultures after normalisation against a-tubulin.
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mitotic defects were also a common feature of the associated
tumour tissues we analysed 23 tumour sections available to us by
NuMA immunostaining and H&E IHC staining. We noted that
the same interphase and mitotic defects were present in these
tumours as in the ascites samples. Representative images and a
summary of the defects observed among the samples are shown in
Figure S2A–D. Furthermore, cell cultures with a high mitotic
index were found to display high mitotic activity in the associated
tumour tissue (Figure S3). Finally, we explored the relationship
between NuMA expression levels in primary cultures and patient
survival. This suggested that patients with moderate to strong
NuMA immunostaining at the spindle poles in primary cultures
have a lower survival rate than patients with weak NuMA
immunostaining, though this preliminary data did not reach
statistical significance (Figure S4), perhaps due to low sample size.
FACS
FACS analysis indicated that only cells from primary cultures
with high NuMA spindle pole staining intensities were aneuploid
(Figure 6H), a statistically significant observation (p = 0.008).
Discussion
In this study we aimed to investigate NuMA1 expression in EOC
and relate this to aneuploidy found in this cancer type. An initial
Oncomine search indicated that NuMA expression is upregulated
in EOC. Our pilot data generated by Affymetrix profiling also
suggested that NuMA1 expression was upregulated in ovarian
cancer. We confirmed this observation at the protein level by IHC,
noting that nuclear NuMA was present at low levels in the nuclei
of normal ovarian stroma and epithelium whereas ovarian primary
tumours had elevated NuMA levels. High levels of NuMA were
associated with tumour grade, disease stage, and lymph node
involvement and inversely to tumour invasion. However, NuMA
expression differed among the four major EOC subtypes. Whereas
NuMA levels decreased with tumour grade and increased with
disease stage in the serous subtype, they increased with tumour
grade in the mucinous subtype and decreased with disease stage in
the endometrioid subtype. In the clear cell subtype only low levels
of NuMA were observed. These differences are likely to reflect the
molecular heterogeneity of EOCs. Recently, EOCs have been
reclassified according to their molecular features into type I (low
grade serous, low grade endometrioid, all mucinous and clear cell
carcinomas) and type II (high grade serous and endometrioid
carcinomas) with mutations mainly in KRAS and PTEN in type I
and mutations in TP53 in type II [25,26]. NuMA levels in our
study were highest in type I EOCs (low grade serous and mucinous
cancers), suggesting NuMA overexpression might be an early
event in carcinogenesis.
Malignant cells derived from ascitic fluids have been used in the
past to generate a wealth of information about immunology and
therapeutics in EOC and it has been proposed that their use could
complement conventional diagnostic procedures [27]. Here, the IF
study of the primary cultures permitted a novel and detailed
examination of evidence of aneuploidy through the identification
of both specific mitotic defects and the interphase consequences of
such defects. Interestingly, we found that high NuMA levels at
spindle poles were associated with high levels of binucleation and
multinucleation. The development of tetraploidy as a result of
failed cytokinesis represents a potential early event in the
development of chromosomal instability (CIN) and eventually
aneuploid karyotypes in tumour cells [10]. The mitotic defects that
we observed in our primary cultures, such as multipolar spindles
and defects in cytokinesis, could explain the incidence of
binucleated and multinucleated cells in these samples. Consistent
with this, we also found a statistically significant correlation
between aneuploidy and high levels of NuMA at the spindle poles
in our cultures.
Having established that NuMA protein levels are upregulated in
EOC and that this is associated with aneuploidy, the next step will
be to determine the functional complicity of NuMA in the
development of this aneuploidy. Work from other investigators has
shown that conditional expression of NuMA in a mouse myeloid
cell line results in aneuploidy and apoptosis [28]. It was suggested
D. Section of normal (N) ovarian epithelial and stromal tissue and matched ovarian cancer (Ca) at x10 and x40 magnification after NuMA
immunostaining. Arrows indicate epithelial cells. Low to medium levels of nuclear NuMA staining can be seen in the normal epithelial cells, with
higher levels of nuclear NuMA staining in the ovarian cancer epithelial cells. E. Analysis of a small ovarian TMA shows that NuMA staining intensity
increases with grade in ovarian tumour tissue.
doi:10.1371/journal.pone.0038945.g001
Figure 2. NuMA expression in different ovarian tumour
subtypes. Low and high NuMA staining patterns observed in cores
from serous, mucinous, endometrial and clear cell carcinomas in a large
scale ovarian TMA. Magnification x10.
doi:10.1371/journal.pone.0038945.g002
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Figure 3. Analysis of NuMA expression in EOC. A. Statistical analysis of the large ovarian cancer TMA showing NuMA expression increases with
disease stage in the mucinous subtype. B. NuMA expression is associated with lymph node involvement (T3cN1MO) (all subtypes). C. NuMA
expression is associated with patient age (all subtypes). D. High levels of NuMA decrease with tumour grade in the serous subtype. E. High NuMA
levels are associated with stage 4 disease in serous EOCs. F. High NuMA levels increase with tumour grade in mucinous EOCs. G. High NuMA levels
decrease with disease stage in endometrioid EOC. H. High NuMA levels decrease with tumour invasion status (T1 to T3) (all subtypes).
doi:10.1371/journal.pone.0038945.g003
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that NuMA overexpression alone was not sufficient to drive
malignant transformation in leukemic cells but that it may
contribute to chromosomal instability, allowing genetic events
promoting cell cycle progression or protection from apoptosis to
occur. One such event could be the acquisition of p53 mutations,
such as those observed in high-grade serous carcinomas [29].
Alternatively, NuMA interacts with the motor protein dynein
during mitosis and it has been suggested that saturation of dynein
activity by NuMA overexpression might antagonise pathways that
cancer cells use to resolve problems such as multipolar spindles.
These typically arise due to the presence of supernumerary
centrosomes, leading to an increase in genomic instability driven
by defects in mitosis [30]. This hypothesis may be applicable to
EOC since the biological consequences of multipolar cell divisions
are consistent with the results observed in our immunofluorescence
work. Centrosomal amplification has also been previously noted in
EOC cells and has been linked to aneuploidy and poor patient
outcome in serous EOC. This phenomenon appears to be caused
by the overexpression of Aurora-A, a member of the serine/
threonine kinase family involved in mitotic events [31,32].
The tumour antigen acrosin binding protein (ACRBP)/OY-
TES-1, has been shown to interact with NuMA. A co-dependent
relationship with a role in paclitaxel resistance in EOC has been
proposed [33]. NuMA overexpression was suggested to cause
mitotic perturbations required for the plasticity of the preneoplas-
tic genome, with co-evolving overexpression of ACRBP as
tumours progress driving the acquisition of traits for the
normalization of these early perturbations that could otherwise
be disadvantageous for cancer cell proliferation by promoting
mitotic catastrophe. The same study also revealed that most
aggressive disease among a cohort of EOC patients was associated
with combined high levels of ACRBP and NuMA. The possibility
that NuMA overexpression acts synergistically with Aurora-A and
ACRBP overexpression to promote aneuploidy, poor survival and
chemoresistance in EOC is intriguing and worthy of further
investigation. As part of this, our preliminary data suggesting that
NuMA expression levels are associated with survival in EOC will
be further explored in a larger sample set to determine whether
this phenomenon is statistically significant.
In conclusion, our data demonstrates for the first time that
NuMA is overexpressed in EOC and that high NuMA levels
correlate with increased mitotic defects and aneuploidy in ascites
cultures derived from patients with ovarian tumours.
Materials and Methods
Cell Lines and Primary Cultures of Malignant Cells
Derived from Ovarian Ascitic Fluids
Cell lines used in this project included four ovarian cancer cell
lines (JAMA-2, SKOV-3, TR175 and 1847), one neuroblastoma
Figure 4. NuMA expression assessed by immunofluorescence
reveals that NuMA localises to the nucleus during interphase
and to the spindle poles during mitosis in cells of ovarian
cancer cell lines and primary ascites cultures and fluorescence
intensities vary among the primary cultures. A. Examples of
interphase nuclei with low (a-d) and high (e-h) NuMA levels, and mitotic
spindles with low (i-l) and high (m-p) NuMA levels at spindle poles.
Green – NuMA, red – a-tubulin, blue - DAPI. Scale bar = 5 mm. B.
Histogram comparing NuMA nuclear fluorescence staining intensities in
four ovarian cell lines, one cell line established from a primary culture
(GYNA0089) and 23 primary cultures derived from ascitic fluid. C.
Histogram comparing NuMA staining intensities at spindle poles in the
subset of cell lines and cultures where a sufficient number of mitotic
cells were for analysis.
doi:10.1371/journal.pone.0038945.g004
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Figure 5. Mitotic and interphase defects in primary cultures. A. Mitotic defects observed at metaphase included (a) asymmetrical bipolar
spindles (b) multiple spindle poles, (c) tripolar spindles, (d) bipolar spindles with multiple spindle poles (e) cells with misplaced and misaligned
spindles (cell periphery outlined). B. Mitotic defects observed at anaphase included lagging chromosomes and anaphase bridging (a -c). C. Mitotic
defects observed during telophase and cytokinesis included (a) abnormal spindles, (b) abnormal cytokinesis with micronuclei formation, (c),
chromatid bridging and (d) formation of unevenly sized daughter cells. D. Examples of (a) binucleation, (b) multinucleation and (c) micronuclei in
primary cultures. Green – NuMA, red – a-tubulin, blue – DAPI in all panels. Scale bar in A and B= 5 mm. Scale bar in C and D= 10 mm. E. Pie chart
illustrating the overall frequency of mitotic defects observed in the primary cultures.
doi:10.1371/journal.pone.0038945.g005
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cell line (SH-SY5Y), one colon adenocarcinoma cell line (SW480),
one cervical cancer cell line (HeLa) and one breast cancer cell line
(MCF7). Cell lines were obtained from Cancer Research UK, the
ECACC and the ATCC Cell Biology Collection. Primary cultures
of cells derived from ovarian ascitic fluids (GYNA0089), ovarian
tumour tissues (BE4163-T1 and AQ70880-T1) or benign tumours
(1153-A1) were established as previously described [18]. Patient
information and clinical data for the ovarian ascitic fluids has been
previously described [18].
Normal Ovarian and Tumour Tissue
Pathological specimens of formalin fixed, paraffin embedded
tissues consisting of sections of normal ovarian tissue and primary
tumours (including tumours that produced the ascites from which
primary cultures were prepared) were obtained from St James’s
University Hospital Histopathology Archive, Leeds. Seven normal
tissues were available, 5 of which also had associated tumour
samples. A total of 23 tumour tissues matching primary cultures
derived from malignant cells were obtained. An additional 25
unrelated primary ovarian tumours with associated clinical data
were identified and used to create an in-house mini tissue
microarray (TMA). The TMA comprised of 9 serous adenocar-
cinomas, 6 endometrioid carcinomas, 2 mucinous, 2 mixed
Mullerian, 5 mixed serous and endometrioid, and 1 adenocarci-
noma. A high density ovarian cancer TMA consisting of 280 cases
of ovarian adenocarcinoma (serous, mucinous and endometrioid),
13 clear cell carcinoma, one transitional cell carcinoma, 20
adjacent normal tissue and 8 normal tissues in duplicate, with
stage and grade information, was obtained from Tissue Array
Networks (OV6161, Tissue Array Network). Accompanying
clinical data included patient age, lymph node involvement,
tumour invasion and metastasis.
Patient Data
Associated clinical details for patients for whom primary
cultures of malignant cells derived from ovarian ascitic fluids were
established, were described previously [18].
Affymetrix Profiling
Data for ovarian cell lines, primary cultures and associated
tumour samples was retrieved from a gene expression microarray
analysis, generated with GeneChip HG-U133 Plus 2.0 Arrays
(Affymetrix) that was normalised using MAS 5.0 as previously
described [18].
Antibodies
The NuMA monoclonal antibody Ab-2 (clone 107-7, Calbio-
chem) was used throughout this study. This has previously been
extensively used for Western blotting, immunofluorescence and
IHC [19,20]. For IF studies rat anti-a-tubulin antibody (1/500,
MCA77G, Serotec) was used to identify microtubules and 49,6-
diamidino-2-phenylindole (DAPI 5 mg/ml, Sigma-Aldrich) used to
stain DNA.
Slot Blotting
Slot blotting of cell lysates was performed as previously
described [18]. 0.01 mg of sample was loaded in each well and
the NuMA monoclonal antibody Ab-2 was used at a 1/400
dilution.
TMA Construction
For the creation of an in-house ovarian TMA a protocol
described by Abd El-Rehim et al [21] was followed. Manual tissue
arrayer punches with a diameter of 0.6 mm (Beecher Instruments,
Inc) were used to create the cores.
Immunohistochemistry
Slides containing whole sections or TMA cores were blocked
with 3% H2O2 in methanol after de-waxing and rehydration.
Antigen retrieval was performed by pressure-cooking slides for 2
minutes in Antigen Unmasking Solution (low pH, Vector
Laboratories). After three 5 minute washes in TBS-Tween-20
(0.2%) the slides were blocked for 10 minutes with 106 casein
(Vector Laboratories) diluted 1:2 in distilled water. After three 5
minute washes with TBS Tween-20 the slides containing whole
sections were placed in Shandon sequenzer units whereas slides
containing TMA sections were laid flat inside a humidified
incubation chamber for incubation with the primary antibody.
NuMA antibody Ab-2 diluted in antibody solution (Zymed) was
applied at 1/300 for whole sections and 1/100 for the TMA
slides. Slides were incubated overnight at 4uC. After three washes
of 5 minutes each with TBS-Tween-20 the slides were incubated
in 100 ml of HRP rabbit/mouse REALTM EnVisionTM (DAKO)
for 30 minutes in the sequenzer units or incubation chamber.
After three final washes with TBS for 5 minutes, developer
solution (DAB+chromagen/substrate buffer, DAKO) was added
for up to 10 minutes until colour development was complete.
Staining was intensified in 0.5% CuSO4 (in 0.9% saline) for 5
minutes. After counterstaining in haematoxylin for 2 minutes, the
sections were dehydrated and mounted in DPX (Sigma). TMA
images were scanned and analyzed using Aperio ImageScope
Viewer software. Slides containing whole sections were viewed
with an Olympus BX61 microscope with Colourview camera
and CellPH software. A labelling scoring system, which applied
two scoring criteria, was utilised [22]. First, the number of
stained nuclei were counted and expressed as a percentage of the
total number of nuclei within the tissue section or core. Second,
the predominant nuclear expression intensity was scored as 0 -
no staining, 1 - trace, 2– weak, 3– medium and 4– strong. The
final score was calculated as the percentage of stained nuclei
multiplied by the predominant expression intensity. Expression
intensity was correlated to associated clinical data including
disease stage, tumour grade, cancer subtype, lymph node
involvement, and metastatic status.
Immunofluorescence
IF staining was performed as described previously [18]. The
NuMA antibody was used at a 1/2000 dilution. To facilitate the
identification and classification of mitotic and interphase defects,
microtubules were visualised with a rat anti-a-tubulin antibody (1/
500, MCA77G, Serotec) and DNA with 49, 6-diamidino-2-
phenylindole (DAPI 5 mg/ml).
Figure 6. NuMA expression in primary cultures is associated with mitotic stage, mitotic defects and aneuploidy. Strong nuclear NuMA
expression was associated with (A) the lowest proportion of telophase cells and (B) the highest proportion of cells with a diffuse metaphase plate.
Strong NuMA spindle pole labelling was associated with high rates of (C) binucleation, (D) multinucleation, (E) a diffuse metaphase plate and (F) the
lowest proportion of cells in cytokinesis. (G) Intermediate spindle pole staining was associated with the lowest proportion of cells exhibiting a
cytokinesis defect. (H) FACS analysis revealed that only cells with high levels of NuMA were aneuploid.
doi:10.1371/journal.pone.0038945.g006
NuMA in Epithelial Ovarian Cancer
PLoS ONE | www.plosone.org 9 June 2012 | Volume 7 | Issue 6 | e38945
Indicators of Aneuploidy
Indicators of processes that might lead to aneuploidy, such as
binucleation, multinucleation and the presence of micronuclei,
were recorded by randomly scoring at least 600 DAPI-stained
interphase cells from a minimum of four different fields of view for
each IF labelled primary culture. The mitotic index for each
culture was established by counting the total number of mitotic
cells in each analysis and expressing this as a percentage of the
total number of cells recorded. To determine the incidence, type
[23] and stage (prophase, prometaphase, metaphase, anaphase,
telophase and cytokinesis) of mitotic defects, a minimum of 50
mitotic cells were examined in each culture. Briefly, in prometa-
phase and metaphase any cell with tri- or multipolar spindles was
recorded and metaphase cells with a loose metaphase plate and/or
misplaced/misaligned spindles scored [24]. Cells with lagging
chromosomes or chromosomal bridges were recorded as anaphase
defects. Telophase and cytokinesis defects encompassed chromo-
somal bridging [23], the presence of abnormal midbodies and the
observation of unequally sized daughter cells. All other mitotic
defects were simply classified as ‘‘abnormal’’.
FACS Analysis of Aneuploidy
When cells reached confluence a single cell suspension was
produced by trypsinization. The suspension was centrifuged at
1000 rpm for 5 minutes and supernatant discarded without
disturbing the cell pellet. Cells were washed twice with PBS,
centrifuged and the supernatant discarded. Cells were fixed by
resuspension in 70% ice-cold ethanol for 30 minutes and were
stored at 220uC until used in FACS analysis. After washing with
PBS and resuspension in 900 ml PBS containing 100 mg/ml
RNAse A, the cells were stained with 100 ml of 200 mg/ml
propidium iodide (PI) and incubated for at least 30 minutes at
37uC. Cellular DNA content was measured on a BD LSRII
analyser (Becton Dickinson). The DNA content of the samples was
expressed as flow cytometric histograms using the ModFit LT
software (Verity Software House). DNA aneuploidy was defined as
any populations with distinct additional peaks (s) or when the
DNA index (DI) was outside the normal diploid range of 0.9–1.1.
The DI represents the ratio of the mean channel number of the
tumour samples G0/G1 peak to the mean channel number of the
normal lymphocyte control samples G0/G1 peak. Histograms
with coefficients of variation greater than10% were excluded. At
least 10,000 cells were counted in each sample.
Statistical Analysis
For statistical analysis of the TMA data, Kruskall-Wallis and
Mann-Whitney Tests (Prism 5 Graph Pad) were used to analyse
the classifications of NuMA staining patterns in the TMA, ovarian
cancer and normal ovarian tissue cores. A p-value of ,0.05 was
considered statistically significant. SPSS version 16.0 (SPSS Inc.)
was used for comparison of the intensity of NuMA spindle pole
staining and aneuploidy. The R environment for statistical
computing (R Development Core Team) was used for some
analysis of association between clinical variables and protein
expression (Fisher’s Exact test and the Kruskall-Wallis test).
Supporting Information
Figure S1 NuMA staining patterns in primary tumours
correspond to staining intensities observed in primary
cultures. Sections of primary tumour were immunostained for
NuMA. (a,b) Weak nuclear staining was demonstrated in sample
1101; note spindle pole staining in mitotic cell (arrow) (b). (c,d) The
strongest staining was observed in sample 1125. These findings
mirror the results obtained by immunofluorescence analysis of the
primary ascitic cultures derived from these tumours (Figure 4B).
(TIFF)
Figure S2 Interphase and mitotic defects in cell cultures
of malignant cells derived from ascitic fluids are also
present in associated tumour tissues. A. Binucleated and
multinucleated cells and micronuclei are present in tumour tissues
associated with ascitic cultures that also displayed these defects, as
indicated by the NuMA and H&E staining. Number indicates
patient ID, T indicates tumour sample. B. Various mitotic defects
including multiple spindle poles, tripolar spindles, multipolar
spindles and anaphase bridging are observed in cell cultures of
malignant cells derived from ascitic fluids and in their associated
tumours. IF images are from cell cultures of malignant cells
derived from ascitic fluids. IHC images are from tumour tissue
sections of associated tumour tissues. (For IF images, green –
NuMA, red – a-tubulin, blue – DAPI in all panels) C. Summary of
the mitotic defects observed in the NuMA stained tumour tissues.
D. Summary of mitotic defects observed in the associated H&E
stains.
(TIFF)
Figure S3 Mitotic activity in cell cultures of malignant
cells derived from ascitic fluids is mirrored in associ-
ated tumour tissue samples. A) Tumour tissue sample 1101
with low mitotic activity (mitotic index in culture = 0%). B) Tissue
sample 1124 with high mitotic activity (mitotic index in culture =
1.9%). Arrows indicate mitotic cells.
(PDF)
Figure S4 Survival graph correlating NuMA expression
and ovarian cancer patients’ survival data. Preliminary
data suggests that survival is associated with low NuMA levels in
ovarian cancer patients. A moderate or strong NuMA score results
in a three fold increase in the likelihood of death compared to a
weak NuMA score (HR=2.94, 95% CI [0.62, 13.95], LRT p-
value = 0.137). However, this result is not statistically significant.
(TIFF)
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